[The End of the Smoking Path: The Aspects of Changing Smoking Habits in Psychiatric Care].

Smoking prevalence is particularly high among individuals with psychiatric disorders, and the low success rate of permanent cessation further exacerbates the situation. However, smoking represents a modifiable risk factor, and addressing it can significantly improve patients' health, quality of life, and life expectancy. This review article explores the most common fears and misconceptions - both from patients and healthcare professionals - that may hinder successful cessation. We examine psychological and pharmacological treatments that support cessation, emphasizing options preferred for psychiatric patients. Special attention is given to the use of nicotine replacement therapies, bupropion, and varenicline, as well as their interactions with psychotropic medications. We also discuss recommended strategies for smoking cessation, the latest guidelines regarding pharmacological interventions, and the direct cessation-supporting effects of psychopharmacological agents. In conclusion, targeted support strategies combined with appropriate pharmacological treatment can significantly increase cessation rates, thereby improving the long-term health outcomes and quality of life for psychiatric patients.